HIGH DOSE INTRAVENOUS ANAKINRA TREATMENT IS SAFE AND EFFECTIVE IN SEVERE AND CRITICAL COVID-19 PATIENTS: A PROPENSITY SCORE MATCHED STUDY IN A SINGLE CENTER


Creative Commons License

Bektas M., Yuce S., Ay M., Uyar M., Onder M., Kilic M. I.

European Congress of Rheumatology (EULAR), Milan, İtalya, 31 Mayıs - 03 Haziran 2023, ss.544, (Özet Bildiri) identifier